Skip to main content
Equibles
HUMA logo

HUMA · Humacyte, Inc.

Track HUMA — free

Use HUMA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.60 +0.01 (+1.49%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company will not have sufficient liquidity to fund its operations beyond one year from the issuance of these condensed consolidated financial statements if the Company is unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$168.04M
Shares
277.80M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.60 Open$0.59 Day$0.58–0.61 52W close$0.55–2.48 Avg vol 30d7.9M Short int31.9M · 11.5% float · 3.4d Short vol60% Last earningsAug 12, 2026 DataDec 2020–Sep 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Dec 4, 2026 Est · unconfirmed · in 13 wks
Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.12M
Trailing 12 months
Net income (TTM)
−$96.73M
Trailing 12 months
Revenue growth YoY
+34.9%
Year over year
Operating margin
-5,240.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-58.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+50.7%
Year over year · more shares
Price change (1Y)
-58.6%
Trailing year
Short interest
11.5%
Latest settlement · 3.4 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −36%
below
Price vs 50-day avg −10%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −46%
trailing
YTD return −37%
this year
Relative strength −61%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +41 funds added
Insider flow Accumulating
Net +$24.8K over 90 days · 0% sells
Short interest Rising
11.50% of float · ▲ +1.4% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
172 holders — near 3-yr high, broad support
Squeeze score 69
elevated · 0–100
Fundamentals
Strong
EPS growth +79%
Y/Y
Free cash flow $-105.9M
Balance sheet $15.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 115%
annualized · 1-yr
Max drawdown −78%
past year
ATR 9.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−36% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +41 funds added
Insider flow Accumulating
Net +$24.8K over 90 days · 0% sells
Short interest Rising
11.50% of float · ▲ +1.4% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
172 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 3% Range high $2
vs 200-day avg -36% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HUMA
Humacyte, Inc.
this stock
$168.04M -37.1% — — 11.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.42B +20.5% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.25B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
172
% held
27.5%
Net QoQ
+14.9M sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
64
View
Short & Settlement
Short Interest Rising
Shares short
31.9M
Days to cover
3.4d
Change
+451.2K sh
View
Short Volume
Short vol %
60%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
523.1K
Value
$287.7K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
66.7%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$24.8K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Congressional Trades Sell
Member
Thomas H Tuberville
Amount
$15.0K–$50.0K
Traded
May 3, 2024
View
Financials
Financials
Revenue (FY)
$2.0M
Net income (FY)
$-40.8M
EPS diluted
$-0.26
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
14
View
Proposed Sales
Value
$41.1K
Shares
45.9K
Filed
May 18, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
HUMA -6.9% -15.8% -46.0% +0.6% -37.1%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -7.1% -15.4% -61.1% +0.2% -50.0%
Key facts CIK 1818382 CUSIP 44486Q103 13F (30d) 101 filings 101 filers Visit website Investor relations